Cambridge Team Uses AI to Design Avian Flu Vaccine Candidate; Animal Trials Show Broad-Spectrum Protection
A November 2026 *Cell Reports Medicine* study by Cambridge University and other institutions reports that an AI-designed avian influenza candidate vaccine showed broad-spectrum immunity and protection in mice and ferrets, surpassing WHO-based control vaccines. Human clinical trials are next. The team noted AI can speed vaccine antigen design, but the candidate's protective efficacy in humans remains unconfirmed.
Cambridge team uses AI to design avian flu vaccine candidates; animal trials show broad-spectrum protection
A paper published online in Cell Reports Medicine in November 2026 by a team from the University of Cambridge and other institutions reports that a novel avian flu vaccine candidate, designed with AI assistance, demonstrated broad-spectrum immunity and protective effects in mouse and ferret trials. It outperformed the control formulation used in the study, which was based on a WHO candidate vaccine virus.
The next step is to advance to human clinical trials to verify its performance in populations and prepare for potential emergency applications. The team stated that AI-assisted design can accelerate the development of vaccine antigens, and the broadly reactive antigen they designed does not exist in nature. The protective efficacy of this vaccine candidate in humans has not yet been confirmed.
University of Cambridge (https://www.cam.ac.uk/stories/ai-developed-vaccines-against-viruses) | Original paper (https://doi.org/10.1016/j.xcrm.2026.103131)
